Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

    NCT04738812 · start 2022-04-21

    Registered record
    Registry ID
    NCT04738812
    Conditions
    Tuberculosis; HIV-1-infection; Immuno-Deficiency
    Interventions
    Intensified TB treatment (initial phase); WHO standard TB treatment (initial phase)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-04-21
    Completion
    2025-11-12
    Enrolment
    1,330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV-1-infection; Immuno-Deficiency
    InterventionIntensified TB treatment (initial phase); WHO standard TB treatment (initial phase)
    PhasePhase 3
    Registry statusCompleted

  • Bioneer Q-RFIA Clinical Evaluation

    NCT05117788 · start 2022-02-23

    Registered record
    Registry ID
    NCT05117788
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Estimate the diagnostic accuracy of the Bioneer Accupower Q-RFIA PCR kit on IRON qPCR for MTB detection using culture as reference standard. Estimate the diagnostic accuracy of the Bioneer Ac
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-02-23
    Completion
    2027-06-30
    Enrolment
    2,350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionEstimate the diagnostic accuracy of the Bioneer Accupower Q-RFIA PCR kit on IRON qPCR for MTB detection using culture as reference standard. Estimate the diagnostic accuracy of the Bioneer Ac
    PhaseNot recorded
    Registry statusActive not recruiting

  • INSTI's For The Management of HIV-associated TB

    NCT04734652 · start 2022-02-18

    Registered record
    Registry ID
    NCT04734652
    Conditions
    HIV/AIDS; Tuberculosis, Pulmonary
    Interventions
    Biktarvy®; TLD- fixed-drug combination single tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-02-18
    Completion
    2024-08-31
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS; Tuberculosis, Pulmonary
    InterventionBiktarvy®; TLD- fixed-drug combination single tablet
    PhasePhase 2
    Registry statusCompleted

  • Pharmacogenetics-guided Isoniazid Dosing in TB-HIV

    NCT05124678 · start 2021-12-07

    Registered record
    Registry ID
    NCT05124678
    Conditions
    Tuberculosis
    Interventions
    Isoniazid Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-12-07
    Completion
    2022-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid Tablets
    PhasePhase 2
    Registry statusUnknown

  • Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

    NCT05077813 · start 2021-12

    Registered record
    Registry ID
    NCT05077813
    Conditions
    Tuberculosis
    Interventions
    13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB); 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB); The standard therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-12
    Completion
    2022-02
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Intervention13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB) +2 more
    PhasePhase 2
    Registry statusUnknown

  • Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

    NCT04311502 · start 2021-11-05

    Registered record
    Registry ID
    NCT04311502
    Conditions
    HIV; Tuberculosis
    Interventions
    Rifapentine; Rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Clofazimine loading dose; Clofazimine 100 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-11-05
    Completion
    2025-06-24
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionRifapentine; Rifampicin; Isoniazid; Pyrazinamide +3 more
    PhasePhase 2
    Registry statusTerminated

  • Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India

    NCT05040126 · start 2021-10-07

    Registered record
    Registry ID
    NCT05040126
    Conditions
    Pre-Extensively Drug-Resistant Pulmonary TB; Treatment Intolerant Multidrug-Resistant Pulmonary TB; Non-responsive Multidrug-Resistant Pulmonary TB
    Interventions
    Linezolid; Bedaquiline; Pretomanid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-10-07
    Completion
    2024-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-Extensively Drug-Resistant Pulmonary TB; Treatment Intolerant Multidrug-Resistant Pulmonary TB; Non-responsive Multidrug-Resistant Pulmonary TB
    InterventionLinezolid; Bedaquiline; Pretomanid
    PhasePhase 3
    Registry statusUnknown

  • A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

    NCT04179500 · start 2021-09-16

    Registered record
    Registry ID
    NCT04179500
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis; Drug-Resistant Tuberculosis
    Interventions
    Pretomanid; Bedaquiline; moxifloxacin; pyrazinamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-16
    Completion
    2024-07-17
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis +1 more
    InterventionPretomanid; Bedaquiline; moxifloxacin; pyrazinamide
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

    NCT04518228 · start 2021-09-01

    Registered record
    Registry ID
    NCT04518228
    Conditions
    HIV; Tuberculosis
    Interventions
    Bictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG); Atazanavir/ritonavir (ATV/r); Darunavir/ritonavir (DRV/r); Lopinavir/ritonavir (LPV/r); Cobicistat; Ritonavir; First-Line TB Treatment; Second-Line TB Treatment; Doravirine (DOR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-09-01
    Completion
    2025-07-10
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionBictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG) +8 more
    PhaseNot recorded
    Registry statusTerminated

  • Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

    NCT04951986 · start 2021-08-11

    Registered record
    Registry ID
    NCT04951986
    Conditions
    Disseminated Tuberculosis; HIV
    Interventions
    Rifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-11
    Completion
    2026-03
    Enrolment
    732

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisseminated Tuberculosis; HIV
    InterventionRifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Pharmacokinetic Study of Linezolid for TB Meningitis

    NCT03537495 · start 2021-06-21

    Registered record
    Registry ID
    NCT03537495
    Conditions
    Tuberculosis, Meningeal; Linezolid
    Interventions
    Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-06-21
    Completion
    2023-07-20
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Meningeal; Linezolid
    InterventionLinezolid
    PhasePhase 2
    Registry statusCompleted

  • TB-CAPT MTB/XDR Study

    NCT04567368 · start 2021-05-14

    Registered record
    Registry ID
    NCT04567368
    Conditions
    Tuberculosis; Resistance Bacterial; Diagnoses Disease
    Interventions
    Xpert MTB/XDR
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-05-14
    Completion
    2024-12-30
    Enrolment
    753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Resistance Bacterial; Diagnoses Disease
    InterventionXpert MTB/XDR
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

    NCT04551573 · start 2021-05

    Registered record
    Registry ID
    NCT04551573
    Conditions
    Tuberculosis; Hiv
    Interventions
    Rifapentine daily; Rifapentine weekly
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-05
    Completion
    2021-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Hiv
    InterventionRifapentine daily; Rifapentine weekly
    PhasePhase 4
    Registry statusWithdrawn

  • Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)

    NCT04670120 · start 2021-03-01

    Registered record
    Registry ID
    NCT04670120
    Conditions
    Sensitive Pulmonary Tuberculosis
    Interventions
    Pyrifazimine (TBI-166)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-03-01
    Completion
    2021-12-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSensitive Pulmonary Tuberculosis
    InterventionPyrifazimine (TBI-166)
    PhasePhase 2
    Registry statusUnknown

  • Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

    NCT04717908 · start 2021-01-20

    Registered record
    Registry ID
    NCT04717908
    Conditions
    Multidrug Resistant Tuberculosis
    Interventions
    Bedaquiline; Pyrazinamide; Linezolid; Cycloserine; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-20
    Completion
    2024-06-22
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis
    InterventionBedaquiline; Pyrazinamide; Linezolid; Cycloserine +1 more
    PhaseNot applicable
    Registry statusCompleted